Itragreat 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itragreat 200 is indicated for the management of systemic and superficial mycoses, including blastomycosis, histoplasmosis, aspergillosis, onychomycosis, and other infections caused by susceptible fungi. The capsule formulation allows for oral administration, with absorption enhanced when taken with food. Itraconazole demonstrates activity against a wide range of dermatophytes, yeasts, and molds. Dosage and duration of therapy depend on the type and severity of infection, and treatment should be guided by clinical response and laboratory findings. Caution is advised in patients with hepatic impairment or congestive heart failure, and potential drug interactions should be carefully monitored due to itraconazole’s inhibition of CYP3A4 enzymes. Adverse effects may include gastrointestinal disturbances, headache, and elevated liver enzymes. Regular monitoring of liver function tests is recommended during prolonged therapy.

Dosage & How to Use